Catequentinib
Small molecule targets CYP3A4, FGFR1, FLT4, KDR, KIT, MET, PDGFRA, PDGFRB via inhibition
Trials 464 · started per year
Also used as a comparator or background therapy in 15 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03910127 Comparator | Jun 2019 → Dec 2020 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05715398 Background | Feb 2023 → Dec 2024 | non-small cell lung carcinoma | Shanghai Gopherwood Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04963088 Background | Mar 2021 → Mar 2024 | gastric cancer | The First Affiliated Hospital with Nanjing Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT04273815 Background | Jul 2020 → Jan 2021 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07025174 Background | Jun 2025 → Dec 2026 expected | cholangiocarcinoma, gallbladder cancer | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06586242 Background | Apr 2023 → Apr 2025 overdue | esophageal cancer | Xijing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05385068 Background | Jun 2022 → Mar 2024 | malignant epithelial tumor of ovary | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01924195 Comparator | Aug 2013 → Mar 2015 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02332499 Comparator | Dec 2014 → Aug 2016 | colorectal cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07165951 Background | Dec 2025 → May 2028 expected | pancreatic ductal adenocarcinoma | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT03940378 Background | Feb 2019 → Feb 2023 | — | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07358520 Comparator | Jan 2026 → Jan 2027 expected | proteinuria | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06931145 Background | Apr 2025 → Apr 2027 expected | small cell lung carcinoma | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05800080 Background | Apr 2023 → Feb 2024 | gastric cancer | Xijing Hospital | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05612191 Background | — | female reproductive organ cancer, soft tissue sarcoma | Advenchen Laboratories, LLC | Available | No outcome recorded |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 483 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Catequentinib | “A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma” NCT03016819 ↗2“A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 (Catequentinib) to Nivolumab in Solid Tumors” NCT04165330 ↗ “Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers” NCT07438886 ↗ |
| Known as | AL-3818 DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303201 ↗ |
| Known as | AL3818 | “The purpose of this study is to assess the safety and efficacy of Anlotinib (AL3818) combined with pembrolizumab (MK-3475) in treatment-naïve adults with no prior systemic...” NCT04164745 ↗12“Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing...” NCT03768037 ↗ “Anlotinib (AL3818) is an inhibitor targeting multiple receptor tyrosine kinases involved in tumour progression, especially VEGFR 2/3, PDGFRα/β and c-Kit.” NCT04438902 ↗ “Allotinib (AL3818) is manufactured by Zhengda Tianqing Pharmaceutical Group Co., LTD. (CTTQ; Lianyungang, Jiangsu, China) self-developed TKI drugs” NCT06429397 ↗ “BACKGROUND: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling.” PMID 29438373 ↗ Feb 2018 “A Phase II Study of Anlotinib(AL3818) in Patients With Advanced Renal Cell Carcinoma(RCC) That Have Failed Or Are Intolerant To TKIs Therapy” NCT02072044 ↗ “Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers” NCT07438886 ↗ “Other Name: AL3818” NCT03778853 ↗ |
| Known as | ALC | “Anlotinib (ALC) is administered at 12mg/d QD，day1\~14, 21d/cycle.” NCT06506838 ↗ |
| Known as | Allotinib | “Allotinib (AL3818) is manufactured by Zhengda Tianqing Pharmaceutical Group Co., LTD. (CTTQ; Lianyungang, Jiangsu, China) self-developed TKI drugs” NCT06429397 ↗ |
| Known as | ALTN | “Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.” NCT01878448 ↗ |
| Known as | Anlootinib hydrochloride | “Anlootinib hydrochloride is a multi-target tyrosine kinase inhibitor that has shown good efficacy in solid tumors such as NSCLC, ovarian cancer, soft tissue tumors, and...” NCT04223583 ↗ |
| Known as | Anlotinib | “This phase 1b/2 study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in combination with Opdivo (nivilumab) for the treatment patients with of...” NCT04165330 ↗470“Anlotinib is a multi-target tyrosine kinase inhibitor that can target and inhibit vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR),...” NCT07142421 ↗ “Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease...” NCT06043973 ↗ “Sintilimab 200 mg intravenously on day 1, pegaspargase 2500 IU/m² on day 1 with a maximum single dose of 3750 IU, and anlotinib 8 mg orally on days 1-14, repeated every 21 days...” NCT07678229 ↗ “Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive Non-small Cell Lung Cancer(NSCLC): An Exploratory Analysis” NCT07671560 ↗ “Thus, our study aimed to evaluate the efficacy and safety of a new regimen of anlotinib plus PD-1 inhibitor to treat refractory solid tumor.” PMID 37155342 ↗ May 2023 “Treatment comprised up to eight 21-day cycles of sintilimab 200 mg (day 1), pegaspargase 2500 IU/m2 (day 1), and anlotinib 8 mg (days 1-14)” PMID 41774854 ↗ Mar 2026 “Study objective is to evaluate effectiveness response of Camrelizumab + anlotinib in subjects with advanced ovarian clear cell carcinoma” NCT05600998 ↗ “Anlotinib: 8 mg orally once daily, starting on Day 1 of each cycle, taken for 2 consecutive weeks followed by a 1-week rest period.” NCT07239622 ↗ “Anlotinib Hydrochloride Combined With Whole Brain Radiotherapy for the Treatment of Brain Metastases in Small Cell Lung Cancer” NCT06611657 ↗ “Antiangiogenesis targeted drugs: Bevacizumab or Anlotinib Hydrochloride, according to the standard dose treatment.” NCT06878625 ↗ “treated with irinotecan (50 mg/m2/d d1-5 Q3W) in combination with Anlotinib (12 mg Qd, 2 weeks on and 1 week off)” PMID 38310286 ↗ Feb 2024 “Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.” NCT05608785 ↗ “Sintilimab 200mg ivdrip D1 Anlotinib 12mg po D1-14 Peg-aspargase 2500U/m2 im D1 combined with radiotherapy” NCT03936452 ↗ “Anlotinib (D1-14, d22-36, followed by a 21-day cycle, taking medicine for 2 weeks, stopping for 1 week).” NCT04182698 ↗ “A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma” NCT05600998 ↗ “Sintilimab 200mg intravenously on day 1 and Anlotinib 12 mg on days 1-14 once every 3 weeks” NCT04055792 ↗ “Anlotinib is a multi-target TKI developed by Chia Tai Tianqing Pharmaceutical” NCT06585644 ↗ “Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w” NCT05400070 ↗ “Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib” NCT03461185 ↗ “Anlotinib 10mg QD PO from Day 1 to 14 of every 21-day cycle” NCT05385068 ↗ “RTK inhibitor regimen: Anlotinib, 12mg, po., d2\~15, q21d.” NCT06249750 ↗ “anlotinib 10 mg orally once daily for 14 consecutive days” NCT07545213 ↗ “The patients were treated with Candonilimab + anlotinib” NCT05926700 ↗ “Anlotinib: 12 mg orally before breakfast, QD.” NCT06320301 ↗ “Anlotinib （10mg, orally, D1-14, q3w）” NCT07089199 ↗ “Anlotinib:12mg，d1-d14 PO，Q3W” NCT07698054 ↗ “Anlotinib 10mg，po，qd1-14，q3w” NCT06475755 ↗ “Anlotinib 8mg D1-D14 Q3W” NCT07231575 ↗ “or anlotinib 12 mg” NCT06145308 ↗ “Drug: Anlotinib” NCT06678230 ↗ “Anlotinib” NCT04620837 ↗ “Anlotinib” NCT06379087 ↗ “Anlotinib” NCT05883085 ↗ “Anlotinib” NCT03765775 ↗ |
| Known as | Anlotinib dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303201 ↗ |
| Known as | Anlotinib Hydrochloride | “Anlotinib Hydrochloride is a multi-target receptor tyrosine kinase inhibitor with significant inhibitory activity against angiogenesis related kinases (VEGFR1/2/3, FGFR1/2/3,...” NCT04611711 ↗61“Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor that has significant inhibitory activity against angiogenesis related kinases such as VEGFR1/2/3,...” NCT04684017 ↗ “Anlotinib hydrochloride, a novel oral multitarget tyrosine kinase inhibitor, has significant inhibitory activity against angiogenesis-related kinases, such as VEGFR, FGFR,...” PMID 37580661 ↗ Aug 2023 “Anlotinib hydrochloride is a novel oral tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR),...” NCT05539118 ↗ “The purpose of this study is to evaluate the efficacy and safety of Benmelstobart Injection combined with Anlotinib Hydrochloride and chemotherapy as first-line treatment for...” NCT07510594 ↗ “Anlotinib hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for 14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a...” NCT05736952 ↗ “Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit...” NCT06062563 ↗ “Patients receive neoadjuvant therapy with oral anlotinib hydrochloride capsules and intravenous benmelstobart injection, followed by partial nephrectomy for localized renal...” NCT07627464 ↗ “Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated.” NCT04620837 ↗ “Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week” NCT04671303 ↗ “This phase II trial studies how well anlotinib hydrochloride works in treating patients with metastatic pheochromocytoma or paraganglioma.” NCT04860700 ↗ “Before breakfast, anlotinib hydrochloride capsule was taken on an empty stomach, once a day, 1 tablet (10mg) each time.” NCT05089643 ↗ “Anlotinib hydrochloride capsules were given 12 mg once a day, taken for 2 weeks and then discontinued for 1 week” NCT06102928 ↗ “Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.” NCT04720807 ↗ “Drug: Anlotinib The dose of anlotinib hydrochloride is 8 mg per dose, taken orally once daily before breakfast.” NCT05828953 ↗ “osimertinib mesylate tablets 80mg qd and anlotinib hydrochloride capsules 10mg qd day 1-14 of a 21-day cycle” NCT04438902 ↗ “Anlotinib hydrochloride (10mg, d1-d14) will be given every 3 weeks for 3 cycles in induction chemotherapy.” NCT07385079 ↗ “anlotinib hydrochloride (12 mg orally, once daily before breakfast; CTTQ, Lianyungang, Jiangsu, China)” NCT04846452 ↗ “Anlotinib Hydrochloride capsules: once a day,12mg each time, oral administration before breakfast.” NCT04964479 ↗ “Anlotinib hydrochloride: 12mg per capsule, 12 mg PO once daily on Days 1-14, cycled every 21 days” NCT05244993 ↗ “Anlotinib hydrochloride capsules 12 mg will be administered orally once daily before breakfast” NCT07446335 ↗ “Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)” NCT03735264 ↗ “Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin” NCT04300959 ↗ “Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor” NCT04073537 ↗ “Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor” NCT04073550 ↗ “Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor.” NCT05124431 ↗ “Anlotinib hydrochloride capsules combined with Cyclophosphamide+Vinorelbine)” NCT07137884 ↗ “anlotinib hydrochloride combined with cisplatin plus etoposide or pemetrexed” NCT04182698 ↗ “Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.” NCT05145218 ↗ “Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.” NCT05121350 ↗ “Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.” NCT05121363 ↗ “Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.” NCT05913089 ↗ “Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.” NCT06507891 ↗ “Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.” NCT05198531 ↗ “Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.” NCT06010901 ↗ “Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.” NCT05193604 ↗ “Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.” NCT07548177 ↗ “Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.” NCT05481645 ↗ “Anlotinib hydrochloride capsule is a tyrosine kinase inhibitor.” NCT06897579 ↗ “Anlotinib hydrochloride is a multi-target antiangiogenic drug.” NCT04757779 ↗ “Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin” NCT06086197 ↗ “Anlotinib Hydrochloride: 10mg, taken orally before breakfast” NCT07455019 ↗ “TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine” NCT04891900 ↗ “Anlotinib Hydrochloride Capsules” NCT04344158 ↗ “Drug: Anlotinib Hydrochloride” NCT04213118 ↗ “Drug: Anlotinib Hydrochloride” NCT04223583 ↗ “Drug: Anlotinib Hydrochloride” NCT03951571 ↗ “Drug: Anlotinib Hydrochloride” NCT04028778 ↗ “Drug: Anlotinib Hydrochloride” NCT05485350 ↗ “Drug: Anlotinib Hydrochloride” NCT04111913 ↗ “Drug: Anlotinib hydrochloride” NCT06476093 ↗ “Drug: Anlotinib hydrochloride” NCT05883085 ↗ “Drug: Anlotinib Hydrochloride” NCT04042597 ↗ “Drug: Anlotinib Hydrochloride” NCT03765775 ↗ “Anlotinib hydrochloride” NCT04736810 ↗ |
| Known as | Anlotinib hydrochloride capsule | “Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)” NCT04439890 ↗3“Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle” NCT05494060 ↗ “Anlotinib hydrochloride capsule: oral administration, once daily(QD) ;” NCT05068206 ↗ “Drug: Anlotinib Hydrochloride Capsule” NCT05549973 ↗ |
| Known as | Anlotinib Hydrochloride Capsules | “Anlotinib Hydrochloride Capsules (12 mg orally, once daily before breakfast; CTTQ, Lianyungang, Jiangsu, China), Toripalimab (240 mg intravenously, once every 3 weeks; Shanghai...” NCT04718701 ↗4“Anlotinib Hydrochloride Capsules: 12mg, administered on the 1-14th day of each cycle, once a day, about half an hour before breakfast (the time of daily administration should...” NCT05800080 ↗ “Anlotinib hydrochloride capsules is a new type of small molecule multi-target tyrosine kinase inhibitor against angiogenesis.” NCT04888546 ↗ “Anlotinib Hydrochloride Capsules, 12mg/d” NCT03950518 ↗ |
| Known as | Catequentinib (AL3818, Anlotinib) Hydrochloride | “Catequentinib (AL3818, Anlotinib) Hydrochloride” NCT05612191 ↗ |
| Known as | Catequentinib dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303201 ↗ |
| Known as | catequentinib hydrochloride | “A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma” NCT03016819 ↗1“Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers” NCT07438886 ↗ |
| Known as | Focus V | “Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories are co-developing anlotinib (Focus V®) for the treatment of advanced cancer.” PMID 29943374 ↗ Jul 2018 |
| Known as | Hydrochloride anlotinib | “Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets.” NCT05772377 ↗1“Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets.” NCT04772001 ↗ |
| Action | Inhibit | “ALTN is a kinase inhibitor of receptor tyrosine with multi-targets” NCT01874873 ↗2“Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL4303201 ↗ “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL4303201 ↗ |
| Modality | Small molecule | “ALTN is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2 and VEGFR3.” NCT01878448 ↗ |
| Route | Oral | “oral medicine.” NCT01833923 ↗ |
| Target | CYP3A4 | “Catequentinib hydrochloride is a strong Cytochrome enzyme P450 3A4 (CYP3A4) inhibitor” NCT03016819 ↗ |
| Target | FLT4 | “Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL4303201 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL4303201 ↗ |